Benutzer: Gast  Login
Titel:

A novel Cereblon E3 ligase modulator with antitumor activity in gastrointestinal cancer

Dokumenttyp:
Zeitschriftenaufsatz
Autor(en):
Lier, Svenja; Sellmer, Andreas; Orben, Felix; Heinzlmeir, Stephanie; Krauß, Lukas; Schneeweis, Christian; Hassan, Zonera; Schneider, Carolin; Schäfer, Arlette; Pongratz, Herwig; Engleitner, Thomas; Öllinger, Rupert; Kuisl, Anna; Bassermann, Florian; Schlag, Christoph; Kong, Bo; Dove, Stefan; Kuster, Bernhard; Rad, Roland; Reichert, Maximilian; Wirth, Matthias; Saur, Dieter; Mahboobi, Siavosh; Schneider, Günter
Abstract:
Targeted protein degradation offers new opportunities to inactivate cancer drivers and has successfully entered the clinic. Ways to induce selective protein degradation include proteolysis targeting chimera (PROTAC) technology and immunomodulatory (IMiDs) / next-generation Cereblon (CRBN) E3 ligase modulating drugs (CELMoDs). Here, we aimed to develop a MYC PROTAC based on the MYC-MAX dimerization inhibitor 10058-F4 derivative 28RH and Thalidomide, called MDEG-541. We show that a subgroup of gas...     »
Stichworte:
BayBioMS; Cereblon; GSPT1; GSPT2; MYC; PLK1
Zeitschriftentitel:
Bioorganic Chemistry
Jahr:
2021
Seitenangaben Beitrag:
105505
Volltext / DOI:
doi:10.1016/j.bioorg.2021.105505
Verlag / Institution:
Elsevier BV
E-ISSN:
0045-2068
Publikationsdatum:
01.11.2021
 BibTeX